European Heart Journal Supplements (2020) **22** (Supplement J), J54–J64
The Heart of the Matter
doi:10.1093/eurheartj/suaa119

Beyond cardiovascular medicine: potential future uses of icosapent ethyl

Deepak L. Bhatt [1], Mark A. Hull[2], Mingyang Song[3,4,5], Carol Van Hulle[6], Cindy Carlsson[7,8,9,10], M. John Chapman[11,12], and Peter P. Toth[13,14]

[1]*Brigham and Women's Hospital, Heart & Vascular Center and Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA*
[2]*Division of Gastrointestinal and Surgical Sciences, Leeds Institute of Medical Research, St James's University Hospital, University of Leeds, Leeds, LS9 7TF, UK*
[3]*Departments of Epidemiology and Nutrition, Harvard T.H. Chan School of Public Health, 665 Huntington Ave, Boston, MA 02115, USA*
[4]*Clinical and Translational Epidemiology Unit, Mongan Institute, Massachusetts General Hospital and Harvard Medical School, 100 Cambridge Street, Boston, MA 02114, USA*
[5]*Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, 50 Fruit Street, Boston, MA 02114, USA*
[6]*University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA*
[7]*William S. Middleton Memorial Veterans Hospital, Madison VA Geriatric Research, Education and Clinical Center (GRECC), 2500 Overlook Terrace, Madison, WI 53705, USA*
[8]*Division of Geriatrics and Gerontology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA*
[9]*Wisconsin Alzheimer's Disease Research Center (ADRC), 600 Highland Ave, J5/1 Mezzanine, Madison, WI 53792, USA*
[10]*Wisconsin Alzheimer's Institute (WAI), 610 Walnut St Suite 957, Madison, WI 53726, USA*
[11]*Sorbonne University, 21, Rue de l'Ecole de Medicine, 75006 Paris, France*
[12]*Endocrinology-Metabolism Division, Pitie-Salpetriere University Hospital, 47-83, Boulevard de lã Hopital, 75651 Paris Cedex, France*
[13]*CGH Medical Center, 101 East Miller Road, Sterling, IL 61081, USA; and*
[14]*Cicarrone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA*

KEYWORDS
Icosapent ethyl;
Colorectal cancer;
Coronavirus;
Inflammation;
Alzheimer's disease;
Depression

The REDUCE-IT trial demonstrated that icosapent ethyl, an ethyl ester of eicosapentaenoic acid (EPA), reduced cardiovascular events in an at-risk population by a substantial degree. While the cardiovascular protective properties of this compound are now proven, several other potential uses are being actively explored in clinical studies. These areas of investigation include cancer, inflammatory bowel disease, infections, Alzheimer's disease, dementia, and depression. The next decade promises to deepen our understanding of the beneficial effects that EPA may offer beyond cardiovascular risk reduction.

Introduction

The data supporting use of the prescription medication icosapent ethyl in patients similar to those enrolled in the Reduction of Cardiovascular Events with Icosapent Ethyl - Intervention Trial (REDUCE-IT) are robust.[1–8] Several registry analyses have found that these results may be

*Corresponding author. Tel: +1 857 307 1992, Email: DLBhattMD@post.Harvard.edu



Figure Ongoing Research on Icosapent Ethyl Outside of Cardiovascular Prevention. CRC, colorectal cancer; IBD, inflammatory bowel disease; IPE, icosapent ethyl; SPMs, specialized pro-resolving mediators.

applicable to a large proportion of patients with established atherosclerosis involving any arterial bed or with diabetes mellitus.[9-11] Analyses from REDUCE-IT support that the primary mode of cardiovascular benefit is mediated through high blood eicosapentaenoic acid (EPA) levels, with basic science experiments ongoing to delineate the exact downstream molecular mechanisms.[12] REDUCE-IT included ~10% of patients with normal triglycerides.[1,13,14] This subgroup had a similar relative risk reduction as patients with higher triglyceride levels. Some physicians will feel comfortable extrapolating from the current data to these patient subsets even absent further large-scale clinical trial testing—especially in higher risk patients.

Remaining questions in the cardiovascular space include whether higher loading doses might provide incremental value in acute settings, such as at the time of myocardial infarction, ischaemic stroke, or revascularization. Patients with a history of such events have already been shown to have significant benefit from treatment with icosapent ethyl in REDUCE-IT, but might they derive even greater benefit if the drug had been administered at the time of the event? The observation from a prespecified analysis of REDUCE-IT showed that higher levels of on-treatment EPA were highly correlated with lower rates of new heart failure, providing potential support for higher maintenance doses of icosapent ethyl.[12] Furthermore, studies are warranted to see if icosapent ethyl could be used specifically to reduce first or recurrent heart failure.[15] Thus, there is a pressing need for further research of EPA in cardiovascular medicine. Perhaps even more intriguing is the potential utility of EPA in other disease states.

Although the exact mechanisms of action of EPA in reducing cardiovascular events are not fully known, they are likely multifactorial. The lipid effects of EPA may include increased plasma lipoprotein lipase activity and decreased lipogenesis in the liver.[16] The non-lipid effects may include anti-inflammatory properties, anti-oxidant effects, arterial plaque modification and regression, anti-thrombotic and anti-platelet effects, cell membrane stabilization, and enhanced endothelial function.[17,18] The central theme figure captures the potential mechanisms of action for the ensuing discussions in this article (Figure). These mechanisms need to be investigated further in ongoing and future clinical trials.

Potential gastrointestinal applications of eicosapentaenoic acid

Laboratory data support a potential benefit of EPA for the reduction of colorectal cancer (CRC) risk.[19] In a small randomized placebo-controlled trial (RCT) of 55 patients with familial adenomatous polyposis, an inherited CRC predisposition syndrome, it was demonstrated that supplementation with EPA 2 g daily for 6 months reduced the number and size of adenomatous rectal polyps (the benign precursor of the majority of 'sporadic' CRCs) by 20–30%.[20] These findings led to a phase III RCT, the seAFOod Polyp

Prevention Trial, which tested the effect of the same dose of EPA in individuals with 'sporadic' colorectal adenomatous polyps detected at colonoscopy in the English Bowel Cancer Screening Programme (BCSP).[21] Although the intervention did not reduce the primary endpoint of the number of individuals with one or more adenomatous polyps, a statistically significant reduction was observed in the secondary outcome of the number of adenomatous polyps, particularly those in the left colon, an endpoint that is more relevant to contemporary trials conducted in quality-assured colonoscopy programmes, such as the English BCSP. To examine the potential of EPA for primary prevention of CRC, a prespecified ancillary study of colonoscopy outcomes was carried out in the large phase III Vitamin D and Omega-3 Trial (VITAL) of 25 871 US adults free of cancer and cardiovascular disease at enrolment.[22] After treatment with omega-3 fatty acids at a dose of 1 g daily [including 460 mg EPA and 380 mg docosahexaenoic acid (DHA)] for a median of 5.3 years, there was no difference in the risk of either adenomatous or serrated polyps (the other major precursor of CRC). Interestingly, a lower risk of adenomatous polyps was reported in the omega-3 fatty acid group compared with those assigned to placebo among individuals with low plasma levels of omega-3 fatty acids at baseline. A beneficial association of omega-3 fatty acid supplementation was also observed in African-Americans, but not in other racial/ethnic groups. These hypothesis-generating findings of a potential preventive effect of a low dose of omega-3 fatty acids in individuals with low omega-3 fatty acid status or African-American persons need to be validated in future large RCTs.

In addition to potential reduction in CRC risk, recent data support benefit of high marine omega-3 fatty acid intake for survival of patients with established CRC. In a Phase II RCT of EPA 2 g daily in 88 patients undergoing liver resection for CRC liver metastasis, EPA treatment increased overall and disease-free survival and reduced the vascularity score of metastatic tumours compared with placebo.[23] Similar beneficial associations between high EPA intake after CRC diagnosis and improved survival have been reported in observational studies.[24,25] Based on these data, a larger-scale, placebo-controlled phase III RCT [EPA for Metastasis Trial 2 (EMT2), NCT03428477] of treatment with EPA (4 g icosapent ethyl daily) was launched in the UK for patients undergoing liver resection for CRC liver metastasis. The findings of EMT2 are expected to become available in 2023 and will shed light on the potential of integrating adjuvant EPA therapy into management of CRC patients.

In contrast to oral supplementation, two intravenous infusions of mixed omega-3 fatty acids at a dose of 0.2 g/kg/day before and after surgery did not change serum levels of inflammatory markers and, unexpectedly, resulted in more infectious post-operative complications in a recent RCT involving patients undergoing elective surgical resection for primary CRC.[26]

The anti-inflammatory properties of EPA have been investigated in the context of inflammatory bowel disease (IBD). An initial report that EPA reduced relapse risk in Crohn's disease[27] has not been replicated by other RCTs and systematic reviews that suggest no overall benefit from omega-3 fatty acids for the clinical course of Crohn's disease or ulcerative colitis (UC).[28] However, observational studies continue to link omega-3 fatty acid intake and blood levels with reduced IBD risk,[29] and a recent RCT concluded that EPA therapy reduced faecal calprotectin levels in UC patients.[30] Further studies of the precision use of EPA for IBD prevention and treatment in defined circumstances (e.g. maintenance of remission in UC) are warranted.

One mechanism that might explain possible anti-cancer and anti-inflammatory effects of EPA in the gastrointestinal tract is modulation of the gut microbiome.[31] There is evidence that EPA and other omega-3 fatty acids are associated with an increased number of immunomodulatory bacteria, such as *Lactobacillus* and *Bifidobacterium*, and short-chain fatty acid-producing bacteria.[32] In support of the relevance of these microbiome associations with CRC and IBD, many of the EPA-enriched bacteria are found to be depleted in CRC and IBD (e.g. short-chain fatty acid-producing bacteria),[33] whereas the bacteria reduced by EPA may promote CRC (e.g. *Fusobacterium nucleatum*).[34–39] Eicosapentaenoic acid may also modify gut environmental conditions and change the composition of microbes.[40–44] Ongoing clinical trials are investigating the effect of EPA on modulation of the intricate relationship between the gut microbiome and tumour immunity (e.g. NCT03661047, NCT03428477, and NCT04216251).

Eicosapentaenoic acid and infectious disease

Infectious diseases (lower respiratory tract infection, diarrheal diseases, tuberculosis, malaria, and human immunodeficiency virus, among others) are the leading causes of mortality in low-income countries.[45] Bacterial strains resistant to antibiotics continue to arise secondary to spontaneous mutations and antibiotic over-utilization.[46] The ongoing global pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or coronavirus disease 2019 (COVID-19) brought renewed concern and focus to humanity's vulnerability to the rapid, widespread transmission of a dangerous virus against which we have neither vaccine nor treatment.[47] Sepsis continues to pose formidable challenges both in terms of understanding its underlying pathophysiology and instituting effective treatment.[48] Identifying novel approaches to the treatment of infectious diseases remains a major focus of scientific and clinical inquiry worldwide.

Polyunsaturated fatty acids (PUFAs) may exert beneficial effects in the setting of infection.[49] The antibacterial effects of fatty acids were first recognized in the 1880s by Koch.[50] It was reported that the skin microbiome is kept in check by PUFAs produced in dermal layers.[51] The PUFAs exert a complex range of effects that impact bacterial viability and control the intensity of the inflammatory response induced by cellular constituents of the immune system. The omega-3 fatty acid EPA has drawn particular attention in these respects.

Membrane effects of eicosapentaenoic acid

Eicosapentaenoic acid is esterified to phospholipids (principally phosphatidylcholine and phosphatidylethanolamine at the sn-2 site) in the lipid rafts of cell and bacterial

membranes.[52] A broad range of gram-positive (e.g. *Bacillus subtilis*, *Listeria monocytogenes*, *Staphylococcus aureus*) and gram-negative (e.g. *Escherichia coli*, *Helicobacter pylori*, *Pseudomonas aeruginosa*) bacteria, mycobacteria, and cyanobacteria were reported to be susceptible to the growth-inhibiting and cidal effects of EPA when studied *in vitro*.[53,54] Eicosapentaenoic acid induces pathogen injury by altering the fluidity of bacterial membranes and disrupting the cell wall and cell membrane.[55] This results in transmembrane ion and metabolite leaks, alterations in the interactions among membrane proteins, impaired enzyme activity, loss in nutrient uptake capacity, cell lysis, and inability to engage in electron transport and oxidative phosphorylation, among other effects.[56–59] There are no human clinical trials which have evaluated the efficacy of EPA in the setting of active infection independent of antibiotic therapy.[60] Polyunsaturated fatty acids may also inhibit the replication of enveloped viruses.[61] Eicosapentaenoic acid has been reported to inhibit the replication of the hepatitis C virus, an example of an enveloped virus.[62] Because COVID-19 and other SARS-associated coronaviruses are enveloped, it has been suggested that omega-3 fatty acids be tested to resolve infection more quickly and prevent cytokine storm syndrome.[63,64] A number of trials are actively enrolling subjects with COVID-19, or at high risk of infection, to determine the effect of EPA, if any, in preventing infection with SARS-CoV-2 or mitigating inflammatory disease sequelae.[65–68]

Specialized pro-resolving molecules

Cytokine storm syndrome (CSS) is systemic inflammatory response that can be precipitated, for example, by viral infection [COVID-19, Middle East respiratory syndrome coronavirus (MERS), influenza] and gram-negative sepsis.[69] Cytokine storm syndrome is a manifestation of a hyperactivated immune system. In the setting of infection, it is crucial that the immune and inflammatory responses be activated in a way that efficiently clears infection without incurring tissue destruction and death of the host.

Therapeutic efforts to attenuate inflammation and reduce risk for CSS events are extraordinarily challenging. Inflammation is a critical component of host defence. Finding a balance between controlling inflammation without compromising the capacity to fight infection is no simple physiological matter. Molecular signalling pathways that could resolve the inflammatory response in CSS are inappropriately inhibited. Under normal conditions, once infection and injured tissue are cleared, intrinsic safety mechanisms to resolve inflammation are activated. This is mediated by specialized pro-resolving mediators (SPMs) of inflammation.

Specialized pro-resolving mediators (also called immunoresolvents) are formed from arachidonic acid as well as EPA, docosapentaenoic acid, and DHA. These PUFAs are liberated from cell membrane phospholipids and are precursors to the maresins, protectins, resolvins, and lipoxins, all of which are SPMs and participate in the resolution of inflammation. The SPMs bind to highly specific surface receptors on target cells.[70]

A variety of models suggest that EPA beneficially impacts inflammatory tone through SPMs and other mechanisms. The E series resolvins are downstream metabolites of EPA. RvE1 inhibits cytokine production, reduces leucocyte infiltration, promotes both neutrophil apoptosis and macrophage phagocytic activity to clear cellular and inflammatory debris (i.e. efferocytosis) and is a more potent anti-inflammatory agent than aspirin or dexamethasone.[71,72] RvE2 also inhibits neutrophil infiltration and induces potent anti-inflammatory activity.[73] Both RvE1 and RvE2 stimulate IL-10 production.[74] In an experimental murine model of aspiration pneumonia, the infusion of RvE1 reduced intrapulmonary levels of numerous interleukins and cytokines, increased bacterial clearance, reduced neutrophil infiltration, and increased survival.[75] The therapeutic utility of RvE1 is being evaluated in a variety of scenarios, including infection and inflammatory diseases.

Eicosapentaenoic acid and its downstream metabolites, the E series resolvins, may offer novel approaches to the treatment and/or prevention of infection and cytokine storm that need to be further investigated in large, well-controlled clinical trials.

Potential uses of eicosapentaenoic acid in Alzheimer's disease, dementia, and depression

Alzheimer's disease and dementia

Dementia due to Alzheimer's disease (AD) is a devastating illness leading to progressive neurodegenerative changes and cognitive decline. In 2019, there were roughly 50 million people living with dementia worldwide.[76] The number of people living with dementia due to AD is expected to triple by 2050.[76] Alzheimer's disease is characterized by a chronic, progressive neurodegeneration resulting from the accumulation of fibrillary proteins in the form of beta-amyloid (Aβ) plaques and hyperphosphorylated tau tangles.[77] Overaccumulation of these substances leads to dysfunction of synapses and neuronal loss.[78] Importantly, these neurodegenerative changes begin decades before clinically apparent disease.[79,80] The National Institute on Aging (NIA)-Alzheimer's Association developed research criteria for defining the asymptomatic or preclinical stages of AD as well as progression to mild cognitive impairment (MCI) and AD[81] based on *in vivo* measures of beta-amyloid and hyerphosphorylated tau and neurodegeneration, along with metrics of cognitive ability. Despite their centrality to clinical AD, the cause of dysregulation of beta-amyloid and tau proteins, and subsequent onset of dementia, is poorly understood. Likewise, not everyone who has AD pathology develops symptoms of dementia. A number of other factors from genetics to lifestyle to environmental exposures are likely to influence the onset and course of AD.[82–85]

Indeed, AD often coexists with vascular dementia, which is the second most common cause of dementia after AD.[86,87] Even in the absence of diagnosable vascular dementia, cerebrovascular pathology can be a major risk factor for clinically diagnosed AD and cognitive decline.[88] One post-mortem pathology study found that cerebrovascular disease was evident in 80% of people diagnosed with AD.[89] Vascular risk factors, such as reduced regional cerebral blood flow in areas of the brain related to memory and

learning[90] and arterial stiffness,[91] are related to deficits in cognitive ability. Other cardiovascular risk factors, such as smoking, hypertension, diabetes, hypercholesterolaemia, and elevated body mass index, have been associated with markers of dementia risk, such as lower grey matter volume and reduced white matter integrity.[92] Cerebrovascular dysfunction may be part of the pathophysiology of AD or these risk factors may lower the threshold at which AD pathology burden leads to observable symptoms of dementia.[93,94] More than likely, vascular dysfunction acts synergistically with neurodegenerative changes and leads to cognitive impairment.[93]

Like beta-amyloid and hyperphosphorylated tau accumulation, cerebral dysfunction occurs early in the development of AD pathology and decades before symptoms begin. Yet, the effects of treating such early vascular dysfunction in the brain are poorly understood. There is some evidence that therapeutics which lower risk for vascular dysfunction, such as antihypertensives, also lower the risk for MCI and AD.[95,96] Other cardiovascular risk factors, such as high cholesterol levels, have been associated with MCI and AD risk.[97,98] However, the relationship between circulating cholesterol and cholesterol in the brain is complex, and randomized clinical trials of statins have generally failed to show any therapeutic benefit on cognitive dysfunction.[99] Another potential target for therapeutics are triglycerides and triglyceride-rich lipoproteins. The brain is a cholesterol-rich organ and enzymes involved in lipid transport or metabolism have been linked to risk for AD.[100] The e4 variant of the Apolipoprotein E gene, for example, has long been known to increase risk for AD.[101] Apolipoprotein E plays a role in the catabolism of triglyceride-rich lipoproteins. Another enzyme, lipoprotein lipase, which is critical to the metabolism of triglyceride-rich lipoproteins, is related to both AD pathology and to cardiovascular risk factors and hypertriglyceridaemia.[102,103]

Eicosapentaenoic acid may improve arterial function and cerebral blood flow, attenuating adverse brain changes related to β-amyloid protein, and improving cognition in animals—changes that need to be investigated for protection against AD.[104–107] This agent is readily available for use and has a good safety profile, making it a favourable agent to consider for AD prevention. Currently, Carlsson *et al*. are conducting a small randomized clinical trial to determine if EPA beneficially affects cerebrovascular function or cognitive performance in cognitively healthy adults at increased risk for AD called Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid (BRAVE-EPA) (NCT02719327).[108]

Depression and n-3 polyunsaturated fatty acids: spotlight on eicosapentaenoic acid

Cardiovascular disease and depression represent the two most common causes of disability in high-income countries, and it has been argued that a recurrent depressed mood may be the 'most important driver of overall quality of life'.[109] Nutritional factors, such as dietary consumption of omega-3 and omega-6 PUFAs, for which a marked reduction in the ratio of omega-3/omega-6 PUFAs has been observed in recent decades,[110] may constitute a relevant molecular basis of depressive disorders.

Biological mechanisms implicated in depression

A number of biological mechanisms may be operative in depression; these include effects on the autonomic nervous system, platelet receptors and function, coagulation factors, proinflammatory cytokine production, endothelial function, and neurohormonal factors; a role for genetic factors, potentially involving variants in key genes of neurotransmitter transport, such as that for serotonin, cannot be excluded. Consequently, drugs which increase monoamine availability, and notably serotonin, represent key therapeutics in major depression. However, many patients respond partially or become refractory to treatment by monoamines as shown in the VAST-D randomized clinical trial, and therefore novel therapeutic approaches are warranted.[111]

Clinical relevance of omega-3 polyunsaturated fatty acids to treatment of depression

Over the period of the past 5 years, evidence has suggested a potential role for EPA in treatment of depression. The meta-analyses of Sarris *et al*.[112] and of Hallahan *et al*.[113] were instrumental in providing experimental evidence for the potential benefits of omega-3 PUFAs when administered as dietary supplements to patients with depression. These analyses revealed that the symptoms of depression were attenuated by consumption of omega-3 PUFA dietary supplements. The analysis of Sarris *et al*.[112] showed moderate benefit of EPA-predominant PUFA preparations as an adjunct to conventional anti-depressant therapy in patients with diagnosed depression. However, the study of Hallahan *et al*.,[113] which included 35 randomized, placebo-controlled intervention trials, indicated that DHA-predominant omega-3 PUFAs did not improve depression symptoms relative to placebo, whereas EPA-predominant preparations (>50% EPA) did. Overall, these findings are consistent with those reported in an RCT, which showed that EPA (as an adjuvant to maintenance medication) exerted greater efficacy compared with DHA or placebo in attenuation of mild-to-moderate depression.[114]

Transport and metabolism of eicosapentaenoic acid

Although EPA is synthesized primarily in the liver by enzymatic elongation and desaturation of precursors, such as α-linolenic acid (ALA), it is the exogenous dietary route which most effectively results in increase in circulating EPA concentrations.[115] Circulating EPA occurs primarily in esterified form in the phospholipids, cholesteryl esters, and triglycerides of plasma lipoproteins, (up to ≈ 40 nmol/mL plasma), with minor amounts bound to plasma proteins (<1 nmol/mL).[116,117] It is the latter form which is readily available for uptake by cells and tissues, and indeed in which EPA may be transported into the brain.[115] Absolute tissue levels of EPA in brain are several-fold lower than those of both ALA and DHA (<25 nmol/g as compared to ≈10 000 nmol/g for the latter). The explanation appears to reside in the short half-life and rapid metabolism of EPA in brain tissue, part of which occurs by β-oxidation.[115]

Brain metabolism of eicosapentaenoic acid: role of microglial cells

By which mechanisms might EPA lead to attenuation of the symptoms of depression? A critical element appears to involve brain microglial cells, which preferentially esterify EPA, leading to intracellular EPA concentrations which are two-fold or more higher than those of DHA; this ratio can be compared with an inverse ratio corresponding to an ~100-fold excess of DHA to EPA in whole brain.[115] Microglial cells are found throughout the brain and spinal cord, representing 10–15% of all nervous tissue cells. Importantly, they represent the resident macrophages of the central nervous system, and as such, are active immuno-inflammatory cells.

Evidence in human subjects and in animal models indicates that mood disorders may be associated with dysfunction of the innate and adaptive immune systems.[118] Moreover, chronic inflammation appears to be a critical factor in the formation and maintenance of major depression in some patients; indeed, depression manifests more frequently in patients displaying chronic inflammatory disease states, such as type 2 diabetes, obesity, and rheumatoid arthritis.[119] While the mechanisms which underlie these disorders are complex, evidence is forthcoming that proinflammatory cytokines and inflammatory lipid mediators may modify not only the metabolism of neurotransmitters but also neurogenesis and neuroplasticity.[119] Significantly, microglial cells are implicated in the production of proinflammatory cytokines in response to peripheral inflammation.[120] In addition, post-mortem studies in patients with depression have documented microglial activation in several regions of brain tissue, including the frontal cortex.[121] Considered together then, microglial-driven inflammation appears to represent a key feature of chronically stressed brains, and as such, has been suggested to lead to alteration in the plasticity of neuronal synapses.[122]Microglial-driven inflammation in brain tissue may therefore represent a key factor in the aetiology of depression.[123]

It is well established that EPA, like DHA, exhibits a wide range of biological activities, and that several of these are particularly relevant to the pathophysiology of uncontrolled inflammation.[74,124] The biology of these effects is complex and may involve a direct action of the *n*-3 PUFA itself, such as regulation of gene expression, or an effect of one of its multiple metabolites, among which are the resolvins, pro-resolving mediators of inflammation.[74] For EPA specifically, studies in preclinical models have demonstrated both neuroprotective and anti-inflammatory effects.[115] Moreover, EPA and/or its metabolites have been found to potently attenuate inflammation in microglial cells, an effect which may be mediated by the down-regulation of proinflammatory cytokine production.[74]

Beyond modulation of inflammation, EPA inhibits the synthesis of prostaglandin E_2, itself an inhibitor of presynaptic serotonin release.[125] In this context, it is pertinent that low brain serotonin levels are intimately associated with marked behavioural consequences typical of depression.[126]

Therapeutic potential of eicosapentaenoic acid in depression

Emerging evidence supports the hypothesis that dietary EPA supplementation may alleviate symptoms of depression, and that such effects may be mediated through its anti-inflammatory actions on microglial cells on the one hand, and through indirect modulation of synaptic serotonin levels on the other. Based on the available evidence, an International Society for Nutritional Psychiatry Research expert panel suggests that 1–2 g per day of EPA (net EPA from EPA/DHA combinations) may be utilized as adjunctive treatment for the potential treatment of major depressive disorder.[127] Given the importance of depression to public health worldwide, the suggestion that a rigorously designed, adequately powered RCT be undertaken to evaluate the efficacy of EPA in attenuating the symptoms of depression is worthy of consideration.

Conclusion

In conclusion, beyond the established indications for icosapent ethyl, there remain other important populations in which to study this safe and well-tolerated drug. A role in cancer is being actively investigated. A potential role in combating COVID-19, supported by early, limited basic science data, is being investigated in clinical trials. Other ongoing trials will also help to explore possible benefits in gastrointestinal disorders, preclinical or early AD, dementia, and the treatment of major depression as an adjunct to antidepressants. These and other future trials will determine whether there will be a role for EPA-based therapy outside of cardiovascular medicine.

Funding

M.A.H. is a NIHR Senior Investigator. M.S.'s work was supported by the American Cancer Society Mentored Research Scholar Grant (MRSG-17-220-01—NEC) and by the U.S. National Institutes of Health (NIH) grants (R00 CA215314). This paper was published as part of a supplement supported by an unrestricted educational grant from Amarin Pharma, Inc.

Conflict of interest: D.L.B. serves as the Chair and International Principal Investigator for REDUCE-IT, with research funding from Amarin to Brigham and Women's Hospital. D.L.B. discloses the following relationships - Advisory Board: Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, Level Ex, Medscape Cardiology, PhaseBio, PLx Pharma, Regado Biosciences; Board of Directors: Boston VA Research Institute, Society of Cardiovascular Patient Care, TobeSoft; Chair: American Heart Association Quality Oversight Committee; Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (Chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo), Population Health Research Institute; Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Vice-Chair, ACC Accreditation Committee), Baim Institute for Clinical Research (formerly

Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor in Chief, *Journal of Invasive Cardiology*), *Journal of the American College of Cardiology* (Guest Editor; Associate Editor), K2P (Co-Chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), Slack Publications (Chief Medical Editor, Cardiology Today's Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), WebMD (CME steering committees); Other: Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair); Research Funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Idorsia, Ironwood, Ischemix, Lexicon, Lilly, Medtronic, Pfizer, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi Aventis, Synaptic, The Medicines Company; Royalties: Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease); Site Co-Investigator: Biotronik, Boston Scientific, CSI, St. Jude Medical (now Abbott), Svelte; Trustee: American College of Cardiology; Unfunded Research: FlowCo, Merck, Novo Nordisk, Takeda. M.J.C. received research grants and/or consulting and/or speaking fees from: Akcea, Alexion, Amarin, Amgen, AstraZeneca, CSL, Daiichi-Sankyo, Kowa, Merck, Pfizer, Randox, Regeneron, Sanofi, and Unilever. M.A.H. received research grants from Amarin. P.P.T. has served on speaker's bureaus for Amarin, Amgen, Esperion, and Novo Nordisk, and has served as a consultant to Amarin, Amgen, Novartis, and Kowa. C.C., M.S., and C.V.H. received clinical supply of research drug from Amarin.

Data availability

No new data were generated or analysed in support of this review article.

Funding

This paper was published as part of a supplement supported by an unrestricted educational grant from Amarin Pharma, Inc.

References

1. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT, Juliano RA, Jiao L, Granowitz C, Tardif J-C, Ballantyne CM. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. *N Engl J Med* 2019;**380**:11–22.
2. Bhatt DL, Steg PG, Brinton EA, Jacobson TA, Miller M, Tardif J-C, Ketchum SB, Doyle RT, Murphy SA, Soni PN, Braeckman RA, Juliano RA, Ballantyne CM; on behalf of the REDUCE-IT Investigators. Rationale and design of REDUCE-IT: reduction of cardiovascular events with icosapent ethyl-intervention trial. *Clin Cardiol* 2017;**40**:138–148.
3. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT, Juliano RA, Jiao L, Granowitz C, Tardif J-C, Gregson J, Pocock SJ, Ballantyne CM. Effects of icosapent ethyl on total ischemic events: from REDUCE-IT. *J Am Coll Cardiol* 2019;**73**:2791–2802.
4. Bhatt DL, Miller M, Brinton EA, Jacobson TA, Steg PG, Ketchum SB, Doyle RT, Juliano RA, Jiao L, Granowitz C, Tardif J-C, Olshansky B, Chung MK, Gibson CM, Giugliano RP, Budoff MJ, Ballantyne CM; on behalf of the REDUCE-IT Investigators. REDUCE-IT USA: results from the 3,146 patients randomized in the United States. *Circulation* 2020;**141**:367–375.
5. Ganda OP, Bhatt DL, Mason RP, Miller M, Boden WE. Unmet need for adjunctive dyslipidemia therapy in hypertriglyderidemia management. *J Am Coll Cardiol* 2018;**72**:330–343.
6. Bhatt DL. REDUCE-IT: residual cardiovascular risk in statin-treated patients with elevated triglycerides: now we can REDUCE-IT! *Eur Heart J* 2019;**40**:1174–1175.
7. Boden WE, Bhatt DL, Toth PP, Ray KK, Chapman MJ, Luscher TF. Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics. *Eur Heart J* 2020;**41**:2304–2312.
8. Patel PN, Patel SM, Bhatt DL. Cardiovascular risk reduction with icosapent ethyl. *Curr Opin Cardiol* 2019;**34**:721–727.
9. Ferrières J, Bataille V, Puymirat E, Schiele F, Simon T, Danchin N. Applicability of the REDUCE-IT trial to the FAST-MI registry. Are the results of randomized trials relevant in routine clinical practice? *Clin Cardiol* 2020;doi:10.1002/clc.23437.
10. Picard F, Bhatt DL, Ducrocq G, Elbez Y, Ferrari R, Ford I, Tardif J-C, Tendera M, Fox KM, Steg PG. Generalizability of the REDUCE-IT trial in patients with stable coronary artery disease. *J Am Coll Cardiol* 2019;**73**:1362–1364.
11. Wong ND, Fan W, Philip S, Granowitz C, Toth PP. REDUCE-IT eligibility and preventable cardiovascular events in the US population (from the National Health and Nutrition Examination Survey [NHANES]). *Am J Cardiol* 2020. https://www.sciencedirect.com/science/article/pii/S0002914920308614.
12. Pisaniello AD, Nicholls SJ, Ballantyne CM, Bhatt DL, Wong ND. Eicosapentaenoic acid: atheroprotective properties and the reduction of atherosclerotic cardiovascular disease events. *EMJ* 2020;**5**:29–36.
13. Bhatt DL, Steg PG, Miller M, Juliano RA, Ballantyne CM. Reply: ischemic event reduction and triglycerides. *J Am Coll Cardiol* 2019;**74**:1849–1850.
14. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Jiao L, Tardif J-C, Gregson J, Pocock SJ, Ballantyne CM. Reduction in first and total ischemic events with icosapent ethyl across baseline triglyceride tertiles. *J Am Coll Cardiol* 2019;**74**:1159–1161.
15. Block RC, Liu L, Herrington DM, Huang S, Tsai MY, O'Connell TD, Shearer GC. Predicting risk for incident heart failure with omega-3 fatty acids: from MESA. *JACC Heart Fail* 2019;**7**:651–661.
16. *Vascepa [Package Insert]*. Bridgewater, NJ: Amarin Pharma Inc.; 2019.
17. Bazarbashi N, Miller M. Icosapent ethyl: Niche drug or for the masses? *Curr Cardiol Rep* 2020;**22**:104.
18. Borow KM, Nelson JR, Mason RP. Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis. *Atherosclerosis* 2015;**242**:357–366.
19. Cockbain AJ, Toogood GJ, Hull MA. Omega-3 polyunsaturated fatty acids for the treatment and prevention of colorectal cancer. *Gut* 2012;**61**:135–149.
20. West NJ, Clark SK, Phillips RKS, Hutchinson JM, Leicester RJ, Belluzzi A, Hull MA. Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis. *Gut* 2010;**59**:918–925.
21. Hull MA, Sprange K, Hepburn T, Tan W, Shafayat A, Rees CJ, Clifford G, Logan RF, Loadman PM, Williams EA, Whitham D, Montgomery AA. Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double-blind, placebo-controlled, 2 x 2 factorial trial. *Lancet* 2018;**392**:2583–2594.
22. Song M, Lee I-M, Manson JE, Buring JE, Dushkes R, Gordon D, Walter J, Wu K, Chan AT, Ogino S, Fuchs CS, Meyerhardt JA, Giovannucci EL; for the VITAL Research Group. Effect of supplementation with marine omega-3 fatty acid on risk of colorectal adenomas and serrated polyps in the US general population: a prespecified ancillary study of a randomized clinical trial. *JAMA Oncol* 2020;**6**:108–115.
23. Cockbain AJ, Volpato M, Race AD, Munarini A, Fazio C, Belluzzi A, Loadman PM, Toogood GJ, Hull MA. Anticolorectal cancer activity

of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid. *Gut* 2014;**63**:1760–1768.
24. Song M, Zhang X, Meyerhardt JA, Giovannucci EL, Ogino S, Fuchs CS, Chan AT. Marine omega-3 polyunsaturated fatty acid intake and survival after colorectal cancer diagnosis. *Gut* 2017;**66**: 1790–1796.
25. Song M, Ou F-S, Zemla TJ, Shi Q, Limburg P, Alberts SR, Giovannucci E, Meyerhardt J, Chan AT. Postdiagnosis marine omega-3 fatty acid intake and survival of stage III colon cancer in North Center Cancer Treatment Group (NCCTG) phase III trial N0147 (Alliance) [abstract Mo1730]. *Gastroenterology* 2018;**154**: S-787–S-788.
26. Bakker N, van den Helder RS, Stoutjesdijk E, van Pelt J, Houdijk APJ. Effects of perioperative intravenous omega-3 fatty acids in colon cancer patients: a randomized, double-blind, placebo-controlled clinical trial. *Am J Clin Nutr* 2020;**111**:385–395.
27. Belluzzi A, Brignola C, Campieri M, Pera A, Boschi S, Miglioli M. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. *N Engl J Med* 1996;**334**:1557–1560.
28. Lev-Tzion R, Griffiths AM, Leder O, Turner D. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease. *Cochrane Database Syst Rev* 2014;**2**:CD006320.
29. Mozaffari H, Daneshzad E, Larijani B, Bellissimo N, Azadbakht L. Dietary intake of fish, n-3 polyunsaturated fatty acids, and risk of inflammatory bowel disease: a systematic review and meta-analysis of observational studies. *Eur J Nutr* 2020;**59**:1–17.
30. Scaioli E, Sartini A, Bellanova M, Campieri M, Festi D, Bazzoli F, Belluzzi A. Eicosapentaenoic acid reduces fecal levels of calprotectin and prevents relapse in patients with ulcerative colitis. *Clin Gastroenterol Hepatol* 2018;**16**:1268–1275.e1262.
31. Song M, Chan AT. Environmental factors, gut microbiota, and colorectal cancer prevention. *Clin Gastroenterol Hepatol* 2019;**17**: 275–289.
32. Watson H, Mitra S, Croden FC, Taylor M, Wood HM, Perry SL, Spencer JA, Quirke P, Toogood GJ, Lawton CL, Dye L, Loadman PM, Hull MA. A randomised trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal microbiota. *Gut* 2018;**67**:1974–1983.
33. Franzosa EA, Sirota-Madi A, Avila-Pacheco J, Fornelos N, Haiser HJ, Reinker S, Vatanen T, Hall AB, Mallick H, McIver LJ, Sauk JS, Wilson RG, Stevens BW, Scott JM, Pierce K, Deik AA, Bullock K, Imhann F, Porter JA, Zhernakova A, Fu J, Weersma RK, Wijmenga C, Clish CB, Vlamakis H, Huttenhower C, Xavier RJ. Gut microbiome structure and metabolic activity in inflammatory bowel disease. *Nat Microbiol* 2019;**4**:293–305.
34. Song M, Chan AT, Sun J. Influence of the gut microbiome, diet, and environment on risk of colorectal cancer. *Gastroenterol* 2020; **158**:322–340.
35. Kaliannan K, Wang B, Li XY, Kim KJ, Kang JX. A host-microbiome interaction mediates the opposing effects of omega-6 and omega-3 fatty acids on metabolic endotoxemia. *Sci Rep* 2015;**5**:11276.
36. Estaki M, DeCoffe D, Gibson DL. Interplay between intestinal alkaline phosphatase, diet, gut microbes and immunity. *World J Gastroenterol* 2014;**20**:15650–15656.
37. Campbell EL, MacManus CF, Kominsky DJ, Keely S, Glover LE, Bowers BE, Scully M, Bruyninckx WJ, Colgan SP. Resolvin E1-induced intestinal alkaline phosphatase promotes resolution of inflammation through LPS detoxification. *Proc Natl Acad Sci U S A* 2010;**107**:14298–14303.
38. Spite M, Norling LV, Summers L, Yang R, Cooper D, Petasis NA, Flower RJ, Perretti M, Serhan CN. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. *Nature* 2009;**461**: 1287–1291.
39. Campbell EL, Serhan CN, Colgan SP. Antimicrobial aspects of inflammatory resolution in the mucosa: a role for proresolving mediators. *J Immunol* 2011;**187**:3475–3481.
40. Polan CE, McNeill JJ, Tove SB. Biohydrogenation of unsaturated fatty acids by rumen bacteria. *J Bacteriol* 1964;**88**:1056–1064.
41. Kishino S, Takeuchi M, Park S-B, Hirata A, Kitamura N, Kunisawa J, Kiyono H, Iwamoto R, Isobe Y, Arita M, Arai H, Ueda K, Shima J, Takahashi S, Yokozeki K, Shimizu S, Ogawa J. Polyunsaturated fatty acid saturation by gut lactic acid bacteria affecting host lipid composition. *Proc Natl Acad Sci U S A* 2013;**110**:17808–17813.
42. Tilg H, Moschen AR. Food, immunity, and the microbiome. *Gastroenterology* 2015;**148**:1107–1119.
43. Dorrestein PC, Mazmanian SK, Knight R. Finding the missing links among metabolites, microbes, and the host. *Immunity* 2014;**40**: 824–832.
44. Sears CL, Garrett WS. Microbes, microbiota, and colon cancer. *Cell Host Microbe* 2014;**15**:317–328.
45. Holmes KK, Bertozzi S, Bloom BR. Major infectious diseases: key messages from disease control priorities, third edition. In: KK Holmes, S Bertozzi, BR Bloom, P Jha, eds. *Major Infectious Diseases*. Washington (DC): The International Bank for Reconstruction and Development/The World Bank; 2017.
46. Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. *P T* 2015;**40**:277–283.
47. Boccaletti S, Ditto W, Mindlin G, Atangana A. Modeling and forecasting of epidemic spreading: the case of Covid-19 and beyond. *Chaos Solitons Fractals* 2020;**135**:109794.
48. Binnie A, Tsang JLY, Hu P, Carrasqueiro G, Castelo-Branco P, Dos Santos CC. Epigenetics of sepsis. *Crit Care Med* 2020;**48**:745–756.
49. Chanda W, Joseph TP, Guo X-F, Wang W-D, Liu M, Vuai MS, Padhiar AA, Zhong M-T. Effectiveness of omega-3 polyunsaturated fatty acids against microbial pathogens. *J Zhejiang Univer Sci B* 2018; **19**:253–262.
50. Thormar H. *Lipids and Essential Oils as Antimicrobial Agents*. Hoboken, NJ: John Wiley & Sons; 2010.
51. Chen YE, Tsao H. The skin microbiome: current perspectives and future challenges. *J Am Acad Dermatol* 2013;**69**:143–155.
52. Shaikh SR, Kinnun JJ, Leng X, Williams JA, Wassall SR. How polyunsaturated fatty acids modify molecular organization in membranes: insight from NMR studies of model systems. *Biochim Biophys Acta* 2015;**1848**:211–219.
53. Desbois AP, Antimicrobial properties of eicosapentaenoic acid 9C20:5n-3. In: SK Kim, ed. *Marine Microbiology*. Weinheim, Germany: Wiley-VCH Verlag; 2013:351–367.
54. Huang CB, Ebersole JL. A novel bioactivity of omega-3 polyunsaturated fatty acids and their ester derivatives. *Mol Oral Microbiol* 2010;**25**:75–80.
55. Yoon BK, Jackman JA, Valle-Gonzalez ER, Cho NJ. Antibacterial free fatty acids and monoglycerides: biological activities, experimental testing, and therapeutic applications. *Int J Mol Sci* 2018; **19**: 1114.
56. Shin SY, Bajpai VK, Kim HR, Kang SC. Antibacterial activity of eicosapentaenoic acid (EPA) against foodborne and food spoilage microorganisms. *LWT Food Sci Technol* 2007;**40**:1515–1519.
57. Zhang YM, Rock CO. Membrane lipid homeostasis in bacteria. *Nat Rev Microbiol* 2008;**6**:222–233.
58. Desbois AP, Smith VJ. Antibacterial free fatty acids: activities, mechanisms of action and biotechnological potential. *Appl Microbiol Biotechnol* 2010;**85**:1629–1642.
59. Le PNT, Desbois AP. Antibacterial effect of eicosapentaenoic acid against *Bacillus cereus* and *Staphylococcus aureus*: killing kinetics, selection for resistance, and potential cellular target. *Mar Drugs* 2017;**15**:334.
60. Jung SW, Lee SW. The antibacterial effect of fatty acids on Helicobacter pylori infection. *Korean J Intern Med* 2015;**31**:30–35.
61. Thormar H, Isaacs CE, Brown HR, Barshatzky MR, Pessolano T. Inactivation of enveloped viruses and killing of cells by fatty acids and monoglycerides. *Antimicrob Agents Chemother* 1987;**31**: 27–31.
62. Leu GZ, Lin TY, Hsu JT. Anti-HCV activities of selective polyunsaturated fatty acids. *Biochem Biophys Res Commun* 2004;**318**: 275–280.
63. Das UN. Can bioactive lipids inactivate coronavirus (COVID-19)? *Arch Med Res* 2020;**51**:282–286.
64. Berger AA, Sherburne R, Urits I, Patel H, Eskander J. *Icosapent Ethyl—A Successful Treatment for Symptomatic COVID-19 Infections*. 2020. https://www.cureus.com/publish/articles/39133-icosapent-ethyl—a-successful-treatment-for-symptomatic-covid-19-infections/preview?token=K_GvFLfprFB2cyqJukEg&utm_campaign=added_as_coauthor&utm_medium=email&utm_source=author_mailer#article-information-publication-history (19 August 2020).
65. An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals with COVID-19 NCT04

412018. 2020. https://clinicaltrials.gov/ct2/show/NCT04412018 (12 August 2020).
66. PREPARE-IT. Prevention of COVID19 With EPA in Healthcare Providers at Risk - Intervention Trial (PREPARE-IT) NCT04460651. 2020. https://clinicaltrials.gov/ct2/show/NCT04460651 (12 August 2020).
67. A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults in the Era of Coronavirus Disease 2019 (MITIGATE) [NCT04505098]. 2020. https://clinicaltrials.gov/ct2/show/NCT04505098. (14 August 2020).
68. EPA-FFA to Treat Hospitalised Patients With COVID-19 (SARS-CoV-2) [NCT04335032]. 2020. https://clinicaltrials.gov/ct2/show/NCT04335032?term=EPA%2C+covid&draw=2&rank=2 (14 August 2020).
69. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the 'Cytokine Storm' in COVID-19. *J Infect* 2020;**80**:607–613.
70. Serhan CN, Krishnamoorthy S, Recchiuti A, Chiang N. Novel anti-inflammatory–pro-resolving mediators and their receptors. *Curr Top Med Chem* 2011;**11**:629–647.
71. Schwab JM, Chiang N, Arita M, Serhan CN. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. *Nature* 2007;**447**:869–874.
72. Dalli J, Serhan CN. Identification and structure elucidation of the pro-resolving mediators provides novel leads for resolution pharmacology. *Br J Pharmacol* 2019;**176**:1024–1037.
73. Tjonahen E, Oh SF, Siegelman J, Elangovan S, Percarpio KB, Hong S, Arita M, Serhan CN. Resolvin E2: identification and anti-inflammatory actions: pivotal role of human 5-lipoxygenase in resolvin E series biosynthesis. *Chem Biol* 2006;**13**:1193–1202.
74. Serhan CN, Levy BD. Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. *J Clin Invest* 2018;**128**:2657–2669.
75. Seki H, Fukunaga K, Arita M, Arai H, Nakanishi H, Taguchi R, Miyasho T, Takamiya R, Asano K, Ishizaka A, Takeda J, Levy BD. The anti-inflammatory and proresolving mediator resolvin E1 protects mice from bacterial pneumonia and acute lung injury. *J Immunol* 2010;**184**:836–843.
76. Alzheimer's Association.2019 Alzheimer's disease facts and figures. Alzheimers Dement 2019;**15**:321–387.
77. Perl DP. Neuropathology of Alzheimer's disease. *Mt Sinai J Med* 2010;**77**:32–42.
78. Iqbal K, Liu F, Gong C-X, Alonso A. D C, Grundke-Iqbal I. Mechanisms of tau-induced neurodegeneration. *Acta Neuropathol* 2009;**118**:53–69.
79. Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. *N Engl J Med* 2012;**367**:795–804.
80. Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. *Lancet Neurol* 2010;**9**:119–128.
81. Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM, Sperling R, Elliott C, Masliah E, Ryan L, Silverberg N. NIA-AA Research Framework: toward a biological definition of Alzheimer's disease. *Alzheimers Dement* 2018;**14**:535–562.
82. Calderón-Garcidueñas L, Gónzalez-Maciel A, Reynoso-Robles R, Delgado-Chávez R, Mukherjee PS, Kulesza RJ, Torres-Jardón R, Ávila-Ramírez J, Villarreal-Ríos R. Hallmarks of Alzheimer disease are evolving relentlessly in Metropolitan Mexico City infants, children and young adults. APOE4 carriers have higher suicide risk and higher odds of reaching NFT stage V at $\leq$40 years of age. *Environ Res* 2018;**164**:475–487.
83. Lambert J-C, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, Jun G, DeStefano AL, Bis JC, Beecham GW, Grenier-Boley B, Russo G, Thornton-Wells TA, Jones N, Smith AV, Chouraki V, Thomas C, Ikram MA, Zelenika D, Vardarajan BN, Kamatani Y, Lin C-F, Gerrish A, Schmidt H, Kunkle B, Dunstan ML, Ruiz A, Bihoreau M-T, Choi S-H, Reitz C, Pasquier F, Hollingworth P, Ramirez A, Hanon O, Fitzpatrick AL, Buxbaum JD, Campion D, Crane PK, Baldwin C, Becker T, Gudnason V, Cruchaga C, Craig D, Amin N, Berr C, Lopez OL, De Jager PL, Deramecourt V, Johnston JA, Evans D, Lovestone S, Letenneur L, Morón FJ, Rubinsztein DC, Eiriksdottir G, Sleegers K, Goate AM, Fiévet N, Huentelman MJ, Gill M, Brown K, Kamboh MI, Keller L, Barberger-Gateau P, McGuinness B, Larson EB, Green R, Myers AJ, Dufouil C, Todd S, Wallon D, Love S, Rogaeva E, Gallacher J, St George-Hyslop P, Clarimon J, Lleo A, Bayer A, Tsuang DW, Yu L, Tsolaki M, Bossù P, Spalletta G, Proitsi P, Collinge J, Sorbi S, Sanchez-Garcia F, Fox NC, Hardy J, Naranjo MCD, Bosco P, Clarke R, Brayne C, Galimberti D, Mancuso M, Matthews F, Moebus S, Mecocci P, Del Zompo M, Maier W, Hampel H, Pilotto A, Bullido M, Panza F, Caffarra P, Nacmias B, Gilbert JR, Mayhaus M, Lannfelt L, Hakonarson H, Pichler S, Carrasquillo MM, Ingelsson M, Beekly D, Alvarez V, Zou F, Valladares O, Younkin SG, Coto E, Hamilton-Nelson KL, Gu W, Razquin C, Pastor P, Mateo I, Owen MJ, Faber KM, Jonsson PV, Combarros O, O'Donovan MC, Cantwell LB, Soininen H, Blacker D, Mead S, Mosley TH, Bennett DA, Harris TB, Fratiglioni L, Holmes C, de Bruijn RFAG, Passmore P, Montine TJ, Bettens K, Rotter JI, Brice A, Morgan K, Foroud TM, Kukull WA, Hannequin D, Powell JF, Nalls MA, Ritchie K, Lunetta KL, Kauwe JSK, Boerwinkle E, Riemenschneider M, Boada M, Hiltunen M, Martin ER, Schmidt R, Rujescu D, Wang L-S, Dartigues J-F, Mayeux R, Tzourio C, Hofman A, Nöthen MM, Graff C, Psaty BM, Jones L, Haines JL, Holmans PA, Lathrop M, Pericak-Vance MA, Launer LJ, Farrer LA, van Duijn CM, Van Broeckhoven C, Moskvina V, Seshadri S, Williams J, Schellenberg GD, Amouyel P; European Alzheimer's Disease Initiative (EADI). Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. *Nat Genet* 2013;**45**:1452–1458.
84. Mueller KD, Norton D, Koscik RL, Morris MC, Jonaitis EM, Clark LR, Fields T, Allison S, Berman S, Kraning S, Zuelsdorff M, Okonkwo O, Chin N, Carlsson CM, Bendlin BB, Hermann BP, Johnson SC. Self-reported health behaviors and longitudinal cognitive performance in late middle age: results from the Wisconsin Registry for Alzheimer's Prevention. *PLoS One* 2020;**15**:e0221985.
85. Sweeney MD, Montagne A, Sagare AP, Nation DA, Schneider LS, Chui HC, Harrington MG, Pa J, Law M, Wang DJJ, Jacobs RE, Doubal FN, Ramirez J, Black SE, Nedergaard M, Benveniste H, Dichgans M, Iadecola C, Love S, Bath PM, Markus HS, Salman RA, Allan SM, Quinn TJ, Kalaria RN, Werring DJ, Carare RO, Touyz RM, Williams SCR, Moskowitz MA, Katusic ZS, Lutz SE, Lazarov O, Minshall RD, Rehman J, Davis TP, Wellington CL, González HM, Yuan C, Lockhart SN, Hughes TM, Chen CLH, Sachdev P, O'Brien JT, Skoog I, Pantoni L, Gustafson DR, Biessels GJ, Wallin A, Smith EE, Mok V, Wong A, Passmore P, Barkof F, Muller M, Breteler MMB, Román GC, Hamel E, Seshadri S, Gottesman RF, van Buchem MA, Arvanitakis Z, Schneider JA, Drewes LR, Hachinski V, Finch CE, Toga AW, Wardlaw JM, Zlokovic BV. Vascular dysfunction—the disregarded partner of Alzheimer's disease. *Alzheimers Dement* 2019;**15**:158–167.
86. Davey DA. Alzheimer's disease and vascular dementia: one potentially preventable and modifiable disease. Part I: pathology, diagnosis and screening. *Neurodegener Dis Manag* 2014;**4**:253–259.
87. Frantellizzi V, Pani A, Ricci M, Locuratolo N, Fattapposta F, De Vincentis G. Neuroimaging in vascular cognitive impairment and dementia: a systematic review. *J Alzheimers Dis* 2020;**73**:1279–1294.
88. Arvanitakis Z, Capuano AW, Leurgans SE, Bennett DA, Schneider JA. Relation of cerebral vessel disease to Alzheimer's disease dementia and cognitive function in elderly people: a cross-sectional study. *Lancet Neurol* 2016;**15**:934–943.
89. Toledo JB, Arnold SE, Raible K, Brettschneider J, Xie SX, Grossman M, Monsell SE, Kukull WA, Trojanowski JQ. Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. *Brain* 2013;**136**:2697–2706.
90. Rivera-Rivera LA, Turski P, Johnson KM, Hoffman C, Berman SE, Kilgas P, Rowley HA, Carlsson CM, Johnson SC, Wieben O. 4D flow

MRI for intracranial hemodynamics assessment in Alzheimer's disease. *J Cereb Blood Flow Metab* 2016;**36**:1718–1730.
91. Badji A, Sabra D, Bherer L, Cohen-Adad J, Girouard H, Gauthier CJ. Arterial stiffness and brain integrity: a review of MRI findings. *Ageing Res Rev* 2019;**53**:100907.
92. Cox SR, Lyall DM, Ritchie SJ, Bastin ME, Harris MA, Buchanan CR, Fawns-Ritchie C, Barbu MC, de Nooij L, Reus LM, Alloza C, Shen X, Neilson E, Alderson HL, Hunter S, Liewald DC, Whalley HC, McIntosh AM, Lawrie SM, Pell JP, Tucker-Drob EM, Wardlaw JM, Gale CR, Deary IJ. Associations between vascular risk factors and brain MRI indices in UK Biobank. *Eur Heart J* 2019;**40**:2290–2300.
93. Rius-Pérez S, Tormos AM, Pérez S, Taléns-Visconti R. Vascular pathology: cause or effect in Alzheimer disease? *Neurologia* 2018;**33**:112–120.
94. Toledo JB, Xie SX, Trojanowski JQ, Shaw LM. Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI. *Acta Neuropathol* 2013;**126**:659–670.
95. Peters R, Warwick J, Anstey KJ, Anderson CS. Blood pressure and dementia: what the SPRINT-MIND trial adds and what we still need to know. *Neurology* 2019;**92**:1017–1018.
96. Williamson JD, Pajewski NM, Auchus AP, Bryan RN, Chelune G, Cheung AK, Cleveland ML, Coker LH, Crowe MG, Cushman WC, Cutler JA, Davatzikos C, Desiderio L, Erus G, Fine LJ, Gaussoin SA, Harris D, Hsieh M-K, Johnson KC, Kimmel PL, Tamura MK, Launer LJ, Lerner AJ, Lewis CE, Martindale-Adams J, Moy CS, Nasrallah IM, Nichols LO, Oparil S, Ogrocki PK, Rahman M, Rapp SR, Reboussin DM, Rocco MV, Sachs BC, Sink KM, Still CH, Supiano MA, Snyder JK, Wadley VG, Walker J, Weiner DE, Whelton PK, Wilson VM, Woolard N, Wright JT, Wright CB; The SPRINT MIND Investigators for the SPRINT Research Group. Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial. *JAMA* 2019;**321**:553–561.
97. Anstey KJ, Ashby-Mitchell K, Peters R. Updating the evidence on the association between serum cholesterol and risk of late-life dementia: review and meta-analysis. *J Alzheimers Dis* 2017;**56**:215–228.
98. Kivipelto M, Helkala EL, Laakso MP. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. *BMJ* 2001;**322**:1447–1451.
99. Geifman N, Brinton RD, Kennedy RE, Schneider LS, Butte AJ. Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer's disease. *Alzheimers Res Ther* 2017;**9**:10.
100. Santos CY, Snyder PJ, Wu WC, Zhang M, Echeverria A, Alber J. Pathophysiologic relationship between Alzheimer's disease, cerebrovascular disease, and cardiovascular risk: a review and synthesis. *Alzheimers Dement* 2017;**7**:69–87.
101. Brousseau T, Legrain S, Berr C, Gourlet V, Vidal O, Amouyel P. Confirmation of the epsilon 4 allele of the apolipoprotein E gene as a risk factor for late-onset Alzheimer's disease. *Neurology* 1994;**44**:342–344.
102. Xie C, Wang ZC, Liu XF, Yang MS. The common biological basis for common complex diseases: evidence from lipoprotein lipase gene. *Eur J Hum Genet* 2010;**18**:3–7.
103. Christensen KD, Roberts JS, Whitehouse PJ, Royal CDM, Obisesan TO, Cupples LA, Vernarelli JA, Bhatt DL, Linnenbringer E, Butson MB, Fasaye G-A, Uhlmann WR, Hiraki S, Wang N, Cook-Deegan R, Green RC; for the REVEAL Study Group. Disclosing pleiotropic effects during genetic risk assessment for Alzheimer disease: a randomized trial. *Ann Intern Med* 2016;**164**:155–163.
104. Pretorius HT, Schumacher H, Quistorf T, Richards N, Budke E, Menke D. Omega 3 fish oil with purified eicosapentanenoic acid also stimulates cerebral perfusion [abstract]. Presented at Annual Meeting of the Alzheimer's Association International Conference; July 13–18, 2013; Boston, MA.
105. Wen M, Ding L, Zhang L, Cong P, Zhang T, Xu J, Chang Y, Wang Y, Xue C. A comparative study of eicosapentaenoic acid enriched phosphatidylcholine and ethyl ester in improving cognitive deficiency in Alzheimer's disease model rats. *Food Funct* 2018;**9**:2184–2192.
106. Wen M, Ding L, Zhang L, Zhang T, Teruyoshi Y, Wang Y, Xue C. Eicosapentaenoic acid-enriched phosphatidylcholine mitigated Aβ1-42-induced neurotoxicity via autophagy-inflammasome pathway. *J Agric Food Chem* 2019;**67**:13767–13774.
107. Amen DG, Harris WS, Kidd PM, Meysami S, Raji CA. Quantitative erythrocyte omega-3 EPA Plus DHA levels are related to higher regional cerebral blood flow on brain SPECT. *J Alzheimers Dis* 2017;**58**:1189–1199.
108. Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid (BRAVE-EPA) (NCT02719327). 2020. https://clinicaltrials.gov/ct2/show/NCT02719327 (14 August 2020).
109. Hare DL, Toukhsati SR, Johansson P, Jaarsma T. Depression and cardiovascular disease: a clinical review. *Eur Heart J* 2014;**35**:1365–1372.
110. Trebatická J, Hradečná Z, Surovcová A, Katrenčíková B, Gushina I, Waczulíková I, Sušienková K, Garaiova I, Šuba J, Ďuračková Z. Omega-3 fatty-acids modulate symptoms of depressive disorder, serum levels of omega-3 fatty acids and omega-6/omega-3 ratio in children. A randomized, double-blind and controlled trial. *Psychiatry Res* 2020;**287**:112911.
111. Mohamed S, Johnson GR, Chen P, Hicks PB, Davis LL, Yoon J, Gleason TC, Vertrees JE, Weingart K, Tal I, Scrymgeour A, Lawrence DD, Planeta B, Thase ME, Huang GD, Zisook S, Rao SD, Pilkinton PD, Wilcox JA, Iranmanesh A, Sapra M, Jurjus G, Michalets JP, Aslam M, Beresford T, Anderson KD, Fernando R, Ramaswamy S, Kasckow J, Westermeyer J, Yoon G, D'Souza DC, Larson G, Anderson WG, Klatt M, Fareed A, Thompson SI, Carrera CJ, Williams SS, Juergens TM, Albers LJ, Nasdahl CS, Villarreal G, Winston JL, Nogues CA, Connolly KR, Tapp A, Jones KA, Khatkhate G, Marri S, Suppes T, LaMotte J, Hurley R, Mayeda AR, Niculescu AB, Fischer BA, Loreck DJ, Rosenlicht N, Lieske S, Finkel MS, Little JT; and the VAST-D Investigators. Effect of antidepressant switching vs augmentation on remission among patients with major depressive disorder unresponsive to antidepressant treatment: the VAST-D randomized clinical trial. *JAMA* 2017;**318**:132–145.
112. Sarris J, Murphy J, Mischoulon D, Papakostas GI, Fava M, Berk M, Ng CH. Adjunctive nutraceuticals for depression: a systematic review and meta-analyses. *Am J Psychiatry* 2016;**173**:575–587.
113. Hallahan B, Ryan T, Hibbeln JR, Murray IT, Glynn S, Ramsden CE, SanGiovanni JP, Davis JM. Efficacy of omega-3 highly unsaturated fatty acids in the treatment of depression. *Br J Psychiatry* 2016;**209**:192–201.
114. Mozaffari-Khosravi H, Yassini-Ardakani M, Karamati M, Shariati-Bafghi SE. Eicosapentaenoic acid versus docosahexaenoic acid in mild-to-moderate depression: a randomized, double-blind, placebo-controlled trial. *Eur Neuropsychopharmacol* 2013;**23**:636–644.
115. Bazinet RP, Metherel AH, Chen CT, Shaikh SR, Nadjar A, Joffre C, Layé S. Brain eicosapentaenoic acid metabolism as a lead for novel therapeutics in major depression. *Brain Behav Immun* 2020;**85**:21–28.
116. Chen CT, Bazinet RP. beta-Oxidation and rapid metabolism, but not uptake regulate brain eicosapentaenoic acid levels. *Prostaglandins Leukot Essent Fatty Acids* 2015;**92**:33–40.
117. Sung HH, Sinclair AJ, Huynh K, Smith AT, Mellett NA, Meikle PJ, Su XQ. Differential plasma postprandial lipidomic responses to krill oil and fish oil supplementations in women: a randomized crossover study. *Nutrition* 2019;**65**:191–201.
118. Dantzer R. Neuroimmune interactions: from the brain to the immune system and vice versa. *Physiol Rev* 2018;**98**:477–504.
119. Wohleb ES. Neuron-microglia interactions in mental health disorders: "for better, and for worse". *Front Immunol* 2016;**7**:544.
120. Sandiego CM, Gallezot J-D, Pittman B, Nabulsi N, Lim K, Lin S-F, Matuskey D, Lee J-Y, O'Connor KC, Huang Y, Carson RE, Hannestad J, Cosgrove KP. Imaging robust microglial activation after lipopolysaccharide administration in humans with PET. *Proc Natl Acad Sci U S A* 2015;**112**:12468–12473.
121. Torres-Platas SG, Cruceanu C, Chen GG, Turecki G, Mechawar N. Evidence for increased microglial priming and macrophage recruitment in the dorsal anterior cingulate white matter of depressed suicides. *Brain Behav Immun* 2014;**42**:50–59.
122. Capuron L, Lasselin J, Castanon N. Role of adiposity-driven inflammation in depressive morbidity. *Neuropsychopharmacol* 2017;**42**:115–128.

123. Yirmiya R, Rimmerman N, Reshef R. Depression as a microglial disease. *Trends Neurosci* 2015;**38**:637–658.
124. Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. *J Am Coll Cardiol* 2011;**58**:2047–2067.
125. Günther J, Schulte K, Wenzel D, Malinowska B, Schlicker E. Prostaglandins of the E series inhibit monoamine release via EP3 receptors: proof with the competitive EP3 receptor antagonist L-826,266. *Naunyn Schmiedebergs Arch Pharmacol* 2010;**381**:21–31.
126. Crockett MJ, Clark L, Apergis-Schoute AM, Morein-Zamir S, Robbins TW. Serotonin modulates the effects of Pavlovian aversive predictions on response vigor. *Neuropsychopharmacol* 2012;**37**:2244–2252.
127. Guu T-W, Mischoulon D, Sarris J, Hibbeln J, McNamara RK, Hamazaki K, Freeman MP, Maes M, Matsuoka YJ, Belmaker RH, Jacka F, Pariante C, Berk M, Marx W, Su K-P. International society for nutritional psychiatry research practice guidelines for omega-3 fatty acids in the treatment of major depressive disorder. *Psychother Psychosom* 2019;**88**:263–273.